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Abstract: p21, a universal inhibitor of mammalian cyclin-dependent 
kinases (CDK), regulates cell cycle progression by forming vari- 
ous distinct protein complexes with cyclins, CDKs, and the pro- 
liferating cell nuclear antigen. We have overexpressed recombinant 
human p21 in E. coli and purified active p2 1 to near homogeneity 
on a large scale. Crystals of recombinant p21 have been grown in 
the space group P2, a = 157.4, b = 152.7, c = 90.6 A, and fl = 
92.7'. The diffraction data of the recombinant p21 have been col- 
lected to 2.5 and 3.5 8, resolution for the native crystal and two 
heavy atom derivatives of mercury and iridium. 
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The primary control of eukaryotic cell cycle progression is pro- 
vided by the sequential formation, activation, and subsequent in- 
activation of a family of serinekhreonine protein kinases, consisting 
of a catalytic subunit, a CDK (cyclin-dependent kinase), and an 
activating regulatory subunit, a cyclin. The enzymatic activity of a 
CDK is regulated by at least three different mechanisms: cyclin 
binding and activation, subunit phosphorylation, and association 
with and inhibition by a CDK inhibitor (reviewed by Sherr and 
Roberts, 1995). In mammalian cells, there exist at least two dis- 
tinct families of CDK inhibitors, represented by two prototype 
CDK inhibitors, p21 and p16. The p16 family currently includes 
four isolated genes (reviewed by Sherr and Roberts, 1995): p 1 61NK4" 
(also variously known as MTSI, CDK41, and CDKN2), pl5INK4' 
(also known as MTS2,  PI^'^'‘^'), and ~ 1 9 ' ~ ~ ~ ~  (re- 
viewed by Sherr and Roberts, 1995). p16 family inhibitors regulate 
two closely related CDKs  (CDK4 and CDK6) through two distinct 
mechanisms: 1) formation of binary complexes with the catalytic 
CDK4 or CDK6 to prevent activation by cyclin D binding and 
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CAK phosphorylation (Serrano et al., 1993; Aprelikova et al., 1995), 
and 2) formation of inactive ternary pl6-CDK4/6-cyclin  D  com- 
plexes (Hirai et al., 1995). 
The p2 1 family currently includes three isolated genes, p2 1 (also 
known as WAFl, Cip l ,   Sd i l ) ,  ~ 2 7 ~ ' ~ ' ,  and ~ 5 7 ~ " ~  (reviewed by 
Sherr and Roberts, 1995). p21 was first discovered in normal 
human fibroblast cells as a component of a quaternary complex 
consisting of cyclin D, a CDK, p2 I ,  and the proliferating cell 
nuclear antigen [PCNA, (Xiong et al., 1992)], and later shown to 
be a component of most, if  not all, cyclin-CDK complexes (Xiong 
et al., 3993b; Zhang et al., 1993). Newly synthesized p21 and 
PCNA protein was not detected in association with cyclin-CDK in 
cells transformed by a variety of tumor viruses or in p53-deficient 
Li-Fraumeni cells, suggesting that p53 function might regulate 
these higher order complexes (Xiong et al., 1993b). The p21 gene 
is transcriptionally activated by the tumor suppressor p53, and 
mice lacking p21 are defective in GI checkpoint control (El-Deiry 
et al., 1993; Brugarolas et al., 1995; Deng et al., 1995; Waldman 
et al., 1995). In addition to p53 regulation, expression of the p21 
gene has also been found to be regulated by cellular senescence 
(Noda et al., 1994), the myogenic factor MyoD (Halevy et al., 
1995), the antimitogenic growth factor TGF-b  (Datto et al., 1995), 
vitamin D3 (Liu et al., 1996), and recently, CCAAT/enhancer- 
binding protein a  [C/EBPa (Timchenko et al., 1996)], implicating 
the p21 gene in the regulation of a variety of growth control 
pathways. 
p21 protein can regulate cell cycle progression by at least four 
distinct biochemical mechanisms: inactivating cyclin-CDK en- 
zymes (Gu et ai., 1993; Harper et al., 1993; Xiong et al., 1993a), 
inhibiting PCNA-dependent DNA replication (Flores-Rozas et a]., 
1994; Waga et al., 1994), preventing phosphorylation and activa- 
tion of CDKs by CAK (Aprelikova et al., 1995), and disrupting 
E2F-pl07 and E2F-pI30 from association with cyclin A-CDK2 
(Zhu  et al., 1995; Shiyanov et al., 1996). Such diverse biochemical 
functions of p21 largely result from the ability of this small protein 
to associate with several cellular proteins to form various distinct 
complexes, including binary complexes with CDKs, cyclins or 
PCNA, ternary complexes with a CDK and a cyclin, and quater- 
nary complexes with a CDK,  a  cyclin, and PCNA. Deletion anal- 
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ysis has identified two separate domains within the 164-amino acid 
human p21 coding sequence. Residues 1-71 alone are highly ac- 
tive in CDK binding and inhibition, and residues 141-160 effi- 
ciently bind PCNA and inhibit SV40 DNA replication in vitro 
(Chen et al., 1995; Luo et al., 1995; Nakanish et al., 1995). To 
provide a structural basis for the biochemical properties of p2 I ,  we 
have purified recombinant p2 1 on a large scale to near homogene- 
ity. We report here a preliminary analysis of p2 I crystal structure. 
Purification and activig assay o f p 2 l  
The p21 overexpression plasmid PET-p21 was constructed by 
insertion of the human p21 coding region into the vector PET- 
3d (Studier et al., 1990) and transformed into E. coli strain 
BL2 1 (DE3).  The transformed cells were grown in LB culture me- 
dium at 37 "C overnight. The p21 gene was overexpressed in the 
absence of isopropyl P-thiogalactopyranoside (IPTG). Addition of 
0.5 mM IPTG did not significantly enhance the yield of the p21 
protein. About I O  g of the prefrozen cell from a 2-liter culture was 
suspended in 40 mL of extraction buffer containing 20 mM Tris- 
base (pH 7 .3 ,  1 mM EDTA, and 1 mM 2-mercaptoethanol. The 
suspension was passed through a French Press three times at 
1,200 psi, and centrifuged at 27,000 X g on  a Beckman J2-21M/E 
centrifuge at 4 "C for 20 min. The pellet was resuspended in 30 mL 
of 0.2 M NaCI, 20 mM Tris-base, 1 mM EDTA, and 1 mM 
2-mercaptoethanol at pH  7.5. The suspension was heated at 100 "C 
for 5 min under constant shaking, immediately cooled in ice water, 
and centrifuged at 19,000 X g for 20 min at  4 "C. After 30 g of 
ammonium sulfate were slowly added into 100 mL of the super- 
natant, the mixture was stirred for 20 min and centrifuged at 
19,000 X g for 20 min at 4 "C. The pellet was dissolved in about 
15 mL of the extraction buffer and dialyzed against 1 liter of the 
extraction buffer twice (1 h  each)  at  4 "C with slow stirring. The 
supernatant was loaded onto a DEAE-Sepharose CL-6B column 
(2.5 X 25 cm, Sigma, St. Louis, MO) and eluted at 4 "C with a 
buffer of 0.2 M NaCI, 20 mM Tris-base,l mM EDTA,I mM 
2-mercaptoethanol at pH 7.5 with a flow rate of 1 mL/min. p21 
does not bind to DEAE in the presence of 0.2 M NaCl and passed 
through the column. 
A typical batch of purification from 2 liters of bacterial culture 
yielded I O  to 20 mg of the p21 protein with greater than 90% 
purity as estimated by Coomassie blue staining . The recombinant 
p21 protein purified from E.coli retains its biological activity, as 
determined by the inhibition assay of the kinase activity of im- 
munoprecipitated various cyclin-CDK  enzymes (data not shown). 
Two major  technical  difficulties  were  encountered  during 
the large-scale purification of p21. First, p21 protein remained in 
the pellet after the cells were passed through a French press, in- 
dicating that the protein was in the form of an inclusion body.  In 
order to solubilize the p21 protein, the pellet was resuspended in a 
buffer of 0.2 M NaCI, 20 mM Tris-base, 1 mM EDTA, I mM 
2-mercaptoethanol, pH 7.5, and heated for 5 min at 100 "C. The 
gains from this step appeared to be twofold; not only was a large 
amount of p21 recovered from the inclusion body,  but also many 
of the foreign proteins were removed from the sample upon their 
denaturation. The second problem with the purification of p21 was 
the phenomena of protein aggregation, as  observed  as follows: ( I )  
Purified p21 could only be concentrated to approximately 2 mg/ 
mL, while further concentration resulted in substantial loss of the 
protein. (2) When the p21 sample was loaded onto a Superose 6 
column (Pharmacia), the elution profile showed several broad peaks 
corresponding to multiple aggregation states. (3)  The native elec- 
trophoresis gel  of  p21 showed a smear of bands, again suggesting 
the multerization of the protein sample. (4) Laser light dynamic 
scattering could not determine the molecular weight of the purified 
p21, implying that there existed multiple magnitudes of p21 ag- 
gregation. 
Although the purification described above normally yielded full- 
length p21, several batches resulted in the protein with a slightly 
higher mobility and a smaller molecular weight (about 1,000 dal- 
tons less) than full length p21, as seen on a denaturing SDS gel. 
Protein sequencing of the shorter p21 revealed an intact amino 
terminus, suggesting possible cleavage at the carboxyl terminal 
during purification. The precise carboxyl terminal sequence of the 
truncated p21 protein was not determined. The short form of p21 
has an increase in solubility to about 7 mg/mL and appears to be 
less aggregated than full-length p21. 
Crystallization and data collection 
Two crystal forms were obtained from the truncated p21 under 
slightly different conditions. The hexagonal crystals were grown at 
room temperature by dialysis against a buffer containing 20 mM 
Tris-base, 0.5 mM NaN,, 0.5 mM 2-mercaptoethanol, 0.5 mM 
EDTA, 6% polyethylene glycol 3350 (PEG 3350) at pH 8.5, while 
the monoclinic crystals were obtained from the same buffer plus 
0.1 M NaCI. The heavy atom derivatives were prepared by soaking 
the native crystals at 25 "C in a buffer of 20 mM Tris-base at pH 
8.5, 30% PEG 3350, and I O  mM K'IrC1, for  2 weeks or 0.2  mM 
methyl mercury chloride for 3 days. The diffraction data of the 
native and the heavy atom derivatives were collected at room 
temperature in the phosphor image plate system Rigaku RAXIS, 
which was operated with an Rigaku RU200 X-ray generator and 
processed by the program DENZO. 
The hexagonal crystals of the p21 protein are too small for the 
X-ray analysis. The p21 crystals in the monoclinic form have the 
space group P2, with cell dimensions of a = 157.4, b = 152.7, c = 
90.6 A, and /3 = 92.7 O and a unit cell volume of 2,175,152 A'. If 
the calculated value of 18,130 daltons is used as the molecular 
weight of the p21 protein, the Vm values (volume of unit cell/ 
molecular weight) will be 3.7 A' per dalton for 16 molecules in the 
asymmetric unit, 2.5 for 24 molecules, and 2.0 for 30 molecules. 
This calculation suggests that the number of molecules in the 
asymmetric unit of the space  group P2, may range from 16 to 30. 
However, considering the average Vm value of 2.4 A'ldalton for 
protein crystals and the observed hexagonal crystal form of p21,24 
molecules in an aggregation state of trimer or hexamer are likely 
to exist in the asymmetric unit of the monoclinic crystal form. 
The monoclinic crystals diffract well to 2.5 A resolution al- 
though the crystals were as small as 0.1 X 0.3 X l .O mm. The first 
native data was collected from freshly grown crystals with unit cell 
dimensions of a = 157.4, b = 152.7, c = 90.6 A, and P = 92.7". 
In order to circumvent the fact that the unit cell of the heavy atom 
derivatives were significantly reduced by 1 to 2% in all three 
dimensions upon soaking the native p21 crystals in the heavy atom 
stabilization solution, the second native data set was collected from 
crystals that were presoaked in a stabilization buffer (30% PEG 
3350, 20 mM Tris-base at pH 8.5) for  3 days. The cell dimensions 
of the native p21 crystals were reduced to a = 156.0, b = 149.5, 
c = 89.0 A, and /3 = 91.2" after soaking in 30% PEG buffer. 
Soaking the native and derivative crystals in the same 30% PEG 
stabilization buffer yielded similar cell dimensions and thus im- 
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Table 1. Statistics for the diffraction data of p21 
Resolution 
Number  of  reflections 
Complete 
Crystal (A) Total  Unique (%) R," R,.,,,b 
Native 1 2.5 193,962 89,895 62.4 0.076 
Native2 3.0 136,820 64.43 1 78.8 0.110 
Indium 3.5  112,278 25,540 84.1 0. I25 0.265 
Mercury 3.2 107,704 50,783 75.2 0.097  0.320 
Rmergp = &kl El1 - ( I ) l / Z I ,  the inner summation is over duplicated reflec- 
tions,  the  outer  is  over  unique  reflections,  and  the  denominator  is  summarized  over  all 
reflections. 
Riso = ChklFderiuariue - FnariueI /C /zk /Fnot ive .  
proved the isomorphism between the native and derivatives. Sta- 
tistics on the collection of the diffraction data are given in Table 1. 
The crystals of the iridium derivative gradually turned to dark 
brown during 2 weeks of soaking, indicating good occupancy of 
the iridium atoms. The scaling R-factor (Riso in Table 1)  and 
correlation coefficient were 0.348 and 0.465 for the mercury de- 
rivative, and 0.269  and 0.672 for the iridium derivative to 4.0 8, 
resolution.  However,  the  correlation  coefficients  dramatically 
dropped to 0.324 and 0.488 at 3.5 8, resolution, indicating non- 
isomorphism at high resolution. Interpretatoion of difference Pat- 
terson synthesis is under way. 
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